Table 3.
PEDro scale results
| Study | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | ∑ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aschendorf et al. [9] | Y | N | Y | Y | N | N | N | Y | Y | Y | Y | 6 |
| Sanchez-Sanchez et al. [22] | Y | Y | Y | Y | N | N | N | Y | Y | Y | Y | 7 |
| Zeng et al. [23] | Y | Y | Y | Y | N | N | N | Y | Y | Y | Y | 7 |
| Alonso-Fernandez et al. [24] | Y | Y | Y | Y | Y | N | N | Y | Y | Y | Y | 8 |
| Jurišić et al. [25] | Y | N | N | Y | N | N | N | Y | Y | Y | Y | 5 |
| Rowan et al. [27] | Y | Y | Y | Y | N | N | N | Y | Y | Y | Y | 7 |
| Wright et al. [8] | Y | N | Y | N | N | N | N | N | Y | N | Y | 3 |
| Arazi et al. [26] | Y | Y | Y | Y | N | N | Y | Y | Y | Y | Y | 8 |
| Kinnunen et al. [31] | Y | Y | N | N | N | N | N | Y | Y | N | Y | 4 |
| Funch et al. [32] | Y | Y | Y | Y | Y | N | N | Y | Y | Y | Y | 8 |
| Teixeira et al. [29] | Y | Y | N | Y | N | N | N | Y | Y | Y | Y | 6 |
| Teixeira et al. [28] | Y | Y | N | Y | N | N | N | Y | Y | Y | Y | 6 |
| Afyon et al. [30] | Y | N | N | N | N | N | N | Y | Y | Y | Y | 4 |
1—eligibility criteria; 2—random allocation; 3—concealed allocation; 4—baseline comparability; 5—blind subject; 6—blind clinician; 7—blind assessor; 8—adequate follow-up; 9—intention-to-treat analysis; 10—between-group analysis; 11—point estimates and variability; Y—criterion is satisfied; N—criterion is not satisfied; ∑—total awarded points